Viridian Therapeutics, Inc.

This study tested an investigational drug called VRDN-001 in 143 people with thyroid eye disease who did not improve in earlier studies. The drug aims to reduce inflammation and eye bulging by blocking a specific receptor. Researchers measured how many participants had at least a…

This Phase 3 trial tested an investigational drug called veligrotug (VRDN-001) in 188 people with chronic thyroid eye disease. The drug is an antibody that blocks a protein involved in the disease. The main goal was to see if it could reduce eye bulging (proptosis) compared to a …

This completed Phase 3 trial tested a drug called VRDN-001 in 231 people with thyroid eye disease (TED). The drug works by blocking a receptor involved in inflammation and swelling. The main goal was to check safety and tolerability, with secondary goals including measuring chang…

This trial tests whether veligrotug, an antibody that blocks a receptor involved in inflammation, can reduce eye bulging and swelling in people with active thyroid eye disease. Participants receive five infusions of the drug or a placebo. The study measures how many people see a …

This study tested a new drug called VRDN-003 in 87 people with thyroid eye disease (TED). The drug is given as a shot under the skin and targets a protein linked to the disease. The main goal was to check safety and how the drug moves through the body, not yet to measure how well…